Actavis Group, the international generic pharmaceuticals company, announced the launch of a product used to treat schizophrenia and bi-polar disorder in Germany.

The product is sold via Actavis’ third party division, Medis, to other pharmaceutical companies that market the product under their own label. Medis’ customers are the first to market a generic version of this product in Germany. The Actavis product was developed at Actavis’ principal research and development site in Iceland, and is manufactured in Actavis’ production plant in Malta for the German market.

The fact that Actavis completed the development of the product very early, five years prior to patent expiry, made it possible for the company to seize this opportunity. The company’s regulatory affairs staff and the production staff in Malta have worked very hard to make this launch possible at this early stage.

Actavis Ltd is a subsidiary of the Actavis Group, a multinational pharmaceutical organization employing 11,000 people in about 40 countries worldwide. The Maltese operation alone boasts a workforce of no less than 450 highly skilled employees.